Work

Molecular signature of patients with pre-treated urothelial carcinoma (UC) achieving extreme responses to pazopanib (PZP) salvage therapy.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.e15514

Authors: Patrizia Pinciroli, Gopa Iyer, Helen H. Won, Silvana Canevari, Maurizio Colecchia, Filippo G. De Braud, Maria Grazia Daidone, Patrizia Giannatempo, Daniele Raggi, Marzia Pennati, Nadia Zaffaroni, Nicola Nicolai, Roberto Salvioni, Marco Pierotti, David B. Solit, Jonathan E. Rosenberg, Michael F. Berger, Andrea Necchi

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599206933

Cites:

Cited by:

Related to: 10